SPTX
NASDAQ HealthcareSeaport Therapeutics, Inc. - Common Stock
Biotechnology
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors. The company was founded in 2024 and is based in Boston, Massachusetts.
๐ Market Data
| Price | $19.84 |
|---|---|
| Volume | 4,692,704 |
| Market Cap | 1.01B |
| 52-Week High | $23.00 |
| 52-Week Low | $19.50 |
๐ฏ Investment Strategy Scores
SPTX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (62/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Moon Shot (13/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SPTX in your text
Paste any article, transcript, or post โ the tool will extract SPTX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.